gallic acid has been researched along with Cancer of Ovary in 9 studies
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ovarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance." | 1.72 | Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines. ( Abdullah, N; Ahmed, I; Al Bahlani, S; Al Balushi, N; Al Dhahli, B; Burney, IA; Dobretsov, S; Hassan, SI; Tamimi, Y; Tsang, BK, 2022) |
| "CP therapy is related to female ovarian cancer and causes female infertility." | 1.62 | Chemoprotective Effect of Syringic Acid on Cyclophosphamide Induced Ovarian Damage via Inflammatory Pathway. ( Chen, L; Li, Y; Liang, Y; Liu, J; Wang, W; Zhao, S, 2021) |
| "Ovarian cancer is the leading cause of mortality among malignant gynecological tumors." | 1.56 | Effect of Gallic acid and Myricetin on ovarian cancer models: a possible alternative antitumoral treatment. ( Castellanos-Mijangos, RD; Chávez-Munguía, B; González-Horta, C; Hernández-Ramírez, VI; Sánchez-Ramírez, B; Talamás-Rohana, P; Varela-Rodríguez, H; Varela-Rodríguez, L, 2020) |
| "To address this, SKOV3 and OVCAR3 ovarian cancer(OC) cell lines with clear cell and serous histology, two main OC subtypes, were exposed to FASN-inhibitor G28UCM." | 1.56 | Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. ( Colomer, R; Gerner, C; Grunt, TW; López-Rodríguez, ML; Semkova, M; Slany, A; Stübiger, G; Wagner, R; Wuczkowski, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Al Balushi, N | 1 |
| Hassan, SI | 1 |
| Abdullah, N | 1 |
| Al Dhahli, B | 1 |
| Al Bahlani, S | 1 |
| Ahmed, I | 1 |
| Tsang, BK | 1 |
| Dobretsov, S | 1 |
| Tamimi, Y | 1 |
| Burney, IA | 1 |
| Varela-Rodríguez, L | 1 |
| Sánchez-Ramírez, B | 1 |
| Hernández-Ramírez, VI | 1 |
| Varela-Rodríguez, H | 1 |
| Castellanos-Mijangos, RD | 1 |
| González-Horta, C | 1 |
| Chávez-Munguía, B | 1 |
| Talamás-Rohana, P | 1 |
| Grunt, TW | 1 |
| Slany, A | 1 |
| Semkova, M | 1 |
| Colomer, R | 1 |
| López-Rodríguez, ML | 1 |
| Wuczkowski, M | 1 |
| Wagner, R | 1 |
| Gerner, C | 1 |
| Stübiger, G | 1 |
| Sicard, AA | 1 |
| Suarez, NG | 1 |
| Cappadocia, L | 1 |
| Annabi, B | 1 |
| Yang, L | 1 |
| Qu, C | 1 |
| Jin, J | 1 |
| Yang, H | 1 |
| Pei, L | 1 |
| Liu, J | 1 |
| Wang, W | 1 |
| Chen, L | 1 |
| Li, Y | 1 |
| Zhao, S | 1 |
| Liang, Y | 1 |
| Pan, H | 1 |
| Wang, F | 1 |
| Rankin, GO | 2 |
| Rojanasakul, Y | 2 |
| Tu, Y | 1 |
| Chen, YC | 2 |
| Sánchez-Carranza, JN | 1 |
| Díaz, JF | 1 |
| Redondo-Horcajo, M | 1 |
| Barasoain, I | 1 |
| Alvarez, L | 1 |
| Lastres, P | 1 |
| Romero-Estrada, A | 1 |
| Aller, P | 1 |
| González-Maya, L | 1 |
| He, Z | 1 |
| Chen, AY | 1 |
9 other studies available for gallic acid and Cancer of Ovary
| Article | Year |
|---|---|
Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug R | 2022 |
Effect of Gallic acid and Myricetin on ovarian cancer models: a possible alternative antitumoral treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Flavonoids; Gallic Acid; Humans; Mice; Ova | 2020 |
Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.
Topics: Cell Line, Tumor; Cell Membrane; Cell Proliferation; Drug Resistance, Neoplasm; Fatty Acid Synthase, | 2020 |
Functional targeting of the TGF-βR1 kinase domain and downstream signaling: A role for the galloyl moiety of green tea-derived catechins in ES-2 ovarian clear cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Catechin; Cell Line, Tumor; Cell Movement; Female; Gallic Acid; H | 2021 |
Syringic acid regulates suppression of the STAT3/JNK/AKT pathway via inhibition of human ovarian teratoma cancer cell (PA-1) growth-in vitro study.
Topics: Cell Line, Tumor; Cell Proliferation; Female; Gallic Acid; Humans; MAP Kinase Kinase 4; Ovarian Neop | 2021 |
Chemoprotective Effect of Syringic Acid on Cyclophosphamide Induced Ovarian Damage via Inflammatory Pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antioxidants; Chemopr | 2021 |
Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
Topics: Apoptosis; Biflavonoids; Catechin; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Damage; Drug | 2017 |
Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Topics: Acetylcysteine; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Dr | 2018 |
Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Female; Gallic Acid; Gene Expression Regulation, Neoplast | 2016 |